Report

Global prefilled syringes market is projected to witness a CAGR of 10.54% during the forecast period 2025-2032, growing from USD 7.94 billion in 2024 to USD 17.70 billion in 2032. Prefilled syringes market is rapidly growing due to increased prevalence of chronic diseases such as diabetics, cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular disorder. According to the American Cancer Society, 2,041,910 new cancer cases and 618,120 cancer death are predicted to occur in the United States in 2025.
The prefilled syringes market is witnessing rapid growth driven by the increased demand for biologics and biosimilars that require accurate and sterile delivery. The use of prefilled syringes reduces the risk of contamination from countless personnel transferring medications from commercial vials to another container. They also achieve better dosing accuracy, easy administration, and convenience for patients because of their simplicity. Given the increase of chronic conditions such as diabetes and autoimmune conditions, prefilled syringes among other technologies such as safety-engineered syringes, auto-injectors, and the use of aided delivery systems which are publicly supported, are expected to see wider adoption.
Additionally, the leading players in the industry are engaging in collaborative activities, bolstering the market's expansion. For instance, in March 2023, Stevanto Group S.p.A. partnered with Recipharm AB to provide innovative primary packaging to develop and produce pre-filled syringes to be used in Recipharm's soft mist inhalers.
Increasing Awareness Supports Market Expansion
Pre-filled syringes deliver extra safety and a reduced risk of contamination because a pharmacy is not required to handle the preparation of medication. The drug is pre-measured in the syringe and factory-sealed, ensuring sterility, and now in an evaluated state for use that is acutely important for clinical and homecare settings. Many prefilled syringes are equipped with a range of safety features such as retractable or shielded needles, which offer risk-reduction solutions for needlestick injuries and accidental reuse. The immediate visibility of tamper-evident features and labelling decreases medication identification errors, in accordance with the prescribing standards recommendations to provide medications in ready-to-administer, or unit dose dispatch forms, thereby improving patient safety.
As the awareness about prefilled syringes increases, leading pharmaceutical companies are focusing on packaging their products in prefilled syringes to ensure safety and physician convenience. For instance, in May 2023, Nexus Pharmaceuticals, Inc. received FDA approval for EMERPHED, indicated for treating clinically significant hypotension during the administration of any type of anesthesia. The prefilled, ready-to-administer syringes provide some measures of protection against danger in critical care situations.
Innovations Support Market Expansion
The market for prefilled syringes is undergoing transformative innovation fueled by the need for accurate biological drug delivery, patient safety, and affordable healthcare. New material science is ensuring the production of more stable and drug-compatible glass and polymers, while the use of smart technology is allowing for dose tracking and adherence monitoring through IoT-connected devices. Furthermore, safety enabling measures such as auto-retractable needle and passive shielding are being designed for addressing needlestick risks as well as user-centered designs that facilitate self-administration for patients with chronic conditions. All resulting in the acceleration of innovative devices including prefilled syringes because of regulatory pressures for safer delivery systems and the growing need for preparedness for pandemics, as well as green initiatives promoting sustainable and biodegradable materials.
Additionally, in order to ensure safe delivery, leading market players are focusing on launching prefilled syringe identification traceability solutions. For instance, in January 2025, Becton, Dickinson and Company launched the BD iDFill individual pre-fillable syringe identification traceability solution to enable unit level traceability throughout the lifecycle of prefilled syringes.
Diabetics Holds the Largest Share in Prefilled Syringes Market
Diabetes is a chronic disease that requires insulin and injectable therapies for a long duration, and thus, the patient population prefers mode of administration that are easy to use, safe, and deliver accurate dosing. As the world moves towards advanced therapies such as GLP-1 receptor agonists, and more concentrated insulins, the requirement for advanced solutions for administering insulin is increasing. Increasing diabetes prevalence across the globe, along with advancements in drug delivery are providing lucrative growth opportunities for the market. The segment is expected to maintain its status as the largest segment due to increasing innovations and growing efforts of various regulatory bodies to effectively combat the increasing threat of diabetes, driving the growth of the prefilled syringes market. For instance, in July 2024, the FDA approved Vabysmo single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Such approvals are expected to provide lucrative growth opportunities for the market.
North America Dominates the Prefilled Syringes Market
The prefilled syringes market is largely dominated by North America, it benefits from advanced healthcare infrastructure, high prevalence of chronic diseases, and strong presence of some of the world's leading pharmaceutical and biotech companies. Due to the increasing patient and provider awareness about the safety and convenience offered by pre-filled syringes, the market is witnessing rapid expansion in the region. North America also has regulatory support (largely by the FDA) for products, so there are faster timelines for approval and faster timelines related to innovation (such as combining technologies with prefilled syringes). For instance, in March 2024, Schott Pharma invested USD 371 million in a new prefilled syringe manufacturing plant in North Carolina. The aim of this plant is to triple the United States supply of glass and polymer syringes to be able to meet the growing demand.
Impact of U.S. Tariffs on Prefilled Syringes Market
- Rising Production Costs: Tariffs on foreign raw materials such as glass, rubber stoppers, and plastic pieces will lead to increased production costs. Higher costs will be transferred to the pharmaceutical companies, hospitals, and patients.
- Disruption in Supply Chain: The majority of components to make prefilled syringes come from China, Germany, and other countries where tariffs are applied. Delays in these imports can lead to shortages that can affect the delivery of vaccines or biologic drugs.
- Increased Interest in Localized Products: Companies will start to look at manufacturing in the United States for more components to avoid tariffs, but this will take time and investment. Non-tariff countries (mostly India, Southeast Asia) may pick up market share from suppliers in other parts of the world.
- Increased Costs for End-users: Hospitals, clinics, and patients will pay more for prefilled syringes and injectable drugs. Could be a strain on healthcare budgets and particularly damaging for developing markets.
- Lower Innovation: The money that would be used for research and development will take a backseat due to increased import costs. Delayed timelines for next generation of prefilled syringe technologies, such as smart injectors.
Key Players Landscape and Outlook
The rapid rise in biologic drugs and biosimilars requiring exact, sterile delivery in compact devices has made prefilled syringes critical to preserving product integrity and efficacy. Global consistency on vaccination and pandemic preparedness fosters broader adoption of prefilled syringe systems, which are easy to use and improve accuracy of dosing among large groups. The continued focus on drug delivery efficiency and related reduction in healthcare expenditure will continue to drive innovation in smart devices, some with dose-tracking features. Sustainability goals also encourage stakeholder investment in greener materials and designs. With all these combined factors, the outlook for prefilled syringes market growth is compelling.
Moreover, leading market players are focusing on launching new products and technologies to expand their presence in the market. For instance, in January 2025, NIPRO EUROPE GROUP COMPANIES introduced D2F Pre-fillable Glass Syringe System � Silicone Oil-Free to meet the unique and demanding requirements of sensitive drugs and the pharmaceutical industry.